New study tracks quality of life in myeloma patients on selinexor combo

NCT ID NCT05954780

Ongoing Knowledge-focused Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study follows 75 people with relapsed or refractory multiple myeloma who are already taking selinexor combined with bortezomib and dexamethasone. Researchers will track quality of life, side effects, and how the treatment works in everyday medical practice. The goal is to provide real-world evidence that complements earlier clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: selinexor (Nexpovio®) combined with bortezomib and dexamethasone
What this could lead to: If successful, this study could provide doctors with better information on how to manage side effects and improve quality of life for people with multiple myeloma.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove the treatment works better than other options. Results may vary widely among participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Gemeinschaftspraxis für Hämatologie und Onkologie GbR

Ravensburg, Baden-Wurttemberg, 88212, Germany
Medizinische Universität Wien, Universitätsklinik für Innere Medizin I

Vienna, 1090, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.